Slingshot members are tracking this event:
Initiation of two Phase 3 trials for Fitusiran (ALN-AT3), in treating severe hemophilia A and B patients with and without inhibitors is expected in early 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|ALNY||Community voting in process|
Slingshot Insights Explained
Sep 07, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Trials, Fitusiran, Aln-at3, Severe Hemophilia A, Hemophilia B